Background:
• In untreated metastatic colorectal cancer (mCRC) use of fluoropyrimidines (FP), irinotecan (Iri) and oxaliplatin were not associated with disadvantage in overall survival (OS) vs. other initial treatment combinations in the pre-antibody era • Bevacizumab (Bev), a vascular endothelial growth factor antibody shows use as a component to combination therapy, with proven prolongation of progression-free survival (PFS) • FP and Bev have demonstrated safety and efficacy in elderly patients • Comparable efficacy seen in combinations of fluorouracil (FU), Iri and leucovorin (FOLFIRI) + Bev, or the combination chemotherapy capecitabine and Iri (CAPIRI) + Bev Purpose:
• To determine if initial treatment of a sequential escalation strategy of FP plus Bev, followed by the addition of Iri at first progression (Arm A) versus upfront use of a three drug regimen (FP + Iri + Bev) (Arm B) showed non-inferiority in patients with untreated metastatic colorectal cancer Study Design • Prior chemotherapy for mCRC, adjuvant therapy within 6 months before enrollment, cardiac insufficiency greater than New York Heart Association (NYHA) grade II or cardiac ischemic event within 6 months before study start, and major bleeding event within 6 months before study start and untreated brain metastases Primary Outcome:
• Non-inferiority of the time to failure of the strategy (TFS)
• Evaluation of symptomatic toxicities included to the hierarchically structured primary end point Secondary Outcomes:
• PFS (time from randomization to disease progression, use of new anticancer drug, or death)
• OS (time from randomization to death)
• Overall response rate (according to RECIST 1.1)
• Evaluation of efficacy according to molecular subgroups Drug Regimens:
• Arm A: (initial FP + Bev): Either (capecitabine PO 1250mg/m 2 BID on days 1-14, plus Bev IV 7.5mg/kg body weight on day 1, repeated every 3 weeks); OR FU-based (IV on day 1: racemic folinic acid with 400 mg/m 2 , FU bolus of 400 mg/m 2 , FU over 46 hours 2,400 mg/m 2 and 5mg/kg body weight of Bev, repeated every 2 weeks) regimens were administered. After first progression, treatment was continued with CAPIRI + Bev (oral capecitabine 800 mg/m 2 twice daily, days 1-14, IV Iri 200mg/m 2 on day 1 plus Bev at a dose of 7.5 mg/kg body weight infused on day 1, repeated every 3 weeks) or biweekly FOLFIRI + Bev with Iri at a dose of 180 mg/m 2 in addition to the FU regimen described above • Arm B: CAPIRI or FOLFIRI + Bev (FP + Iri + Bev) as described. In arm B, de-escalation of Iri (in the case of at least stable disease for > 6 months) and consecutive re-escalation to the fullafter progression while on de-escalated treatment-was allowed Size 421 Patients: 212 assigned to arm A and 209 to arm B 274 (88.8%) of 421 tumors available for testing of RAS and BRAF mutations Power
• Difference in an early end point in TFS is considered meaningful if the relative benefit is greater than 20%, corresponding to hazard ratio (HR) of less than 0.8 • Aimed to exclude relative disadvantage by sequential treatment of 20% corresponding to a limit for non-inferiority of 8 months (Δ = 2 months) • Non-inferiority shown at a significance level of 5% if the lower limit of the 90% CI (HR) is 0.8 or more
• Initial design required 506 events for TFS, but after interim analysis at 5 years, several factors resulted in reduction to a power of 70% needing 378 events Results
• 
